Infectious Diseases News

PHILADELPHIA--(BUSINESS WIRE)--GSK’s RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk...

CHICAGO--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) and its Chicago area affiliate organizations the South Side Help Center (SSHC) and CALOR will team to host a street protest and give testimony before the Chicago Department of Health’s HIV Planning Committee at an emergency public meeting on Friday, March 13, to oppose and halt planned grant funding cuts. The organizations’ actions are part of an effort to restore funding of AHF's HIV Primary Care Services and SSHC's Early Intervention...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma and COVIRIX Medical collaborate to assess feasibility of adapting Aptar Pharma’s proprietary DPI platform for antiviral delivery....

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (Nasdaq: HYFT), a Bio-Native AI company focused on biologics discovery and AI-driven drug development, today reported financial results for the third quarter of fiscal year 2026, ended January 31, 2026. MindWalk will host its Q3 Fiscal 2026 Earnings Call today at 10:30 AM Eastern Time. Revenue for Q3 was $4.2 million, a 52 percent increase from $2.7 million in Q3 fiscal 2025, marking MindWalk's third consecutive quarter of year-over-year r...

BOSTON--(BUSINESS WIRE)--Routine vaccine visits may no longer exist for many American children, new ZoomRx research finds....

LONDON--(BUSINESS WIRE)--Baseimmune, a biotechnology company leveraging computational protein design to create next-generation immunotherapies, today unveiled its new fibrosis-focused pipeline, beginning with IPF. IPF is a progressive and life-threatening condition marked by aberrant wound healing, dysregulated tissue repair, and persistent activation of pro-fibrotic fibroblasts. Despite decades of research, approved therapies only slow lung function decline and do not halt or reverse progressi...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided a business update. “2025 was an exceptional year for Precision BioSciences marked by meaningful clinical and financial progress. We delivered on what we co...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma initiates a Phase I trial in Australia evaluating ME3241, an anti-PD-1 agonist antibody discovered with FBRI....

--(BUSINESS WIRE)--Connie Norman Transgender Empowerment Center Starts Health Care Services at New Clinic ‘Open for ALL’ Sat. Mar. 14, 2026...